Project Grant R43NS105530

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $478,417 Project Grant (CFDA 93.853) to the University of California, Davis to develop a novel multi-functional extracellular vesicle-based nanotherapeutic for treating multiple sclerosis (MS). The objective is to engineer placenta-derived mesenchymal stem cell-derived extracellular vesicles (PMSC-EVs) with a targeting ligand (LLP2A) to enhance their ability to modulate pathogenic immune cells and promote...

This $405,282 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research investigating the role of antibodies targeting the PLP1 protein and associated myelin complexes in the pathogenesis of multiple sclerosis (MS). The key products and services to be delivered under this 5-year grant include: 1) Screening biobanked serum and...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $647,782 to the San Diego Biomedical Research Institute to conduct research on evaluating the therapeutic potential of hypoxia mimetics in inflammatory demyelinating disease, specifically multiple sclerosis (MS). The key objectives of this 5-year research project are to: 1)...

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...

This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development and validation of Artificial Axons, a novel 3D-printed drug discovery platform for identifying remyelinating compounds to treat multiple sclerosis (MS) and other myelin diseases. The $506,083 award to Artificial Axon Labs Inc., an MIT spinout, aims to achieve two key...

This Project Grant award of $305,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of stem-like T cells in the pathogenesis of multiple sclerosis (MS). The key objectives are to: Rigorously test the hypothesis that the continuing stemness and differentiation of CD4+ T stem-like cells results in functional and transcriptomic diversification under evolving...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to the University of California, Los Angeles (UCLA) to develop a novel therapeutic approach using chimeric antigen receptor (CAR) technology to target amyloid beta (Aβ) aggregates and reduce central nervous system (CNS) inflammation for the treatment of Alzheimer's disease (AD). The project is structured in two phases: the R61 phase will focus on developing and optimizing...

This $440,000 Project Grant award from the National Eye Institute (NEI), under Federal Grant Program 93.867 (Vision Research), aims to develop a novel, disease-targeted anti-angiogenic therapy for treating wet age-related macular degeneration (AMD). The key product being developed is a neutralizing monoclonal antibody that targets a new, CNV-selective angiogenic factor discovered through the awardee's comparative ligandomics technology. This approach differs from currently approved anti-VEGF...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $646,106 to Tulane University to investigate whether inducing the RECK protein could be a novel therapeutic approach to prevent the development and progression of atherosclerosis. The key research objectives are to determine if RECK overexpression in vascular smooth muscle cells and macrophages can inhibit inflammation, tissue remodeling,...